Preconception preparation of women with obesity without comorbidities
DOI: 10.32364/2618-8430-2026-9-3-9
Preconception preparation of women with obesity without comorbidities
A.V. Tiselko1, F.F. Burumkulova2, I.M. Tokeshev3
1 D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproduction, St. Petersburg, Russian Federation
2 Moscow Regional Research Institute of Obstetrics and Gynecology named after аcademician V.I. Krasnopolsky, Moscow, Russian Federation
3 Geropharm LLC, St. Petersburg, Russian Federation
Obesity is a modifiable risk factor for reproductive dysfunction. At a BMI ≥30 kg/m2, time to conception is prolonged, and a risk of subfertility is increased nearly 1.7-fold. Preconception weight correction is a priority strategy for restoring natural fertility and optimizing pregnancy outcomes. Excessive body weight (BW) is associated with anovulation, decreased oocyte quality, impaired endometrial receptivity, increased risks of congenital malformations, gestational diabetes, and preeclampsia, and a risk of surgical delivery and perinatal pathology. Non-pharmacological strategies (diet, physical activity) provide modest weight loss (on average, 3.5 kg within 14 weeks) that is insufficient for ovulation recovery in a significant proportion of patients. Tirzepatide, a dual GIP/GLP-1 receptor agonist, leads to 20–24% weight loss and 40% visceral fat reduction. Rapid recovery of ovulation associated with the therapy and decreased efficacy of oral contraceptives provides a risk of unintended pregnancy; since the drug withdrawal induces metabolic rebound (~14% of lost weight regained over 52 weeks), organized withdrawal and nutritional support should be arranged. Preconception weight correction requires a combination of non-pharmacological strategies, pharmacotherapy, and nutritional support with reliable non-oral contraception throughout the treatment period.
Keywords: obesity, preconception preparation, fertility, incretins, tirzepatide, GLP-1, gestational diabetes, preeclampsia, contraception, metabolic rebound.
For citation: Tiselko A.V., Burumkulova F.F., Tokeshev I.M. Preconception preparation of women with obesity without comorbidities. Russian Journal of Woman and Child Health. 2026;9(3):281–288 (in Russ.). DOI: 10.32364/2618-8430-2026-9-3-9
About the authors:
Alyona V. Tiselko — Dr. Sc. (Med.), Senior Scientific Officer, D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproduction; 3, Mendeleevskaya line, St. Petersburg, 199034, Russian Federation; ORCID iD 0000-0002-2512-833
Fatima F. Burumkulova — Dr. Sc. (Med.), Professor, Leading Scientific Officer at the Department of Obstetrics, Moscow Regional Research Institute of Obstetrics and Gynecology named after аcademician V.I. Krasnopolsky; 22a, Pokrovka str., Moscow, 101000, Russian Federation; ORCID iD 0000-0001-9943-0964
Ilya M. Tokeshev — Medical Marketing Manager, GEROPHARM LLC; 6, bldg. 2, entrance 3, Presnenskaya emb., Moscow, 123112, Russian Federation.
Contact information: Fatima F. Burumkulova, e-mail: fatima-burumkulova@yandex.ru
Financial Disclosure: the review was prepared with the sponsorship of Geropharm LLC.
Conflict of interest: I.M. Tokeshev is an employee of Geropharm LLC. The other authors declare that there is no conflict of interest.
There is no conflict of interest.
Received 04.06.2026.
Revised 24.06.2026.
Accepted 20.07.2026.
2. Алфеерова В.И., Мустафина С.В. Распространенность ожирения во взрослой популяции Российской Федерации (обзор литературы). Ожирение и метаболизм. 2022;19(1):96–105. DOI: 10.14341/omet12809. Alferova V.I., Mustafina S.V. The prevalence of obesity in the adult population of the Russian Federation (literature review). Obesity and metabolism. 2022;19(1):96–105 (in Russ.). DOI: 10.14341/omet12809
3. Souter I., Baltagi L.M., Kuleta D. et al. Women, weight, and fertility: the effect of body mass index on the outcome of superovulation/intrauterine insemination cycles. Fertil Steril. 2011;95(3):1042–1047. DOI: 10.1016/j.fertnstert.2010.11.062
4. Sermondade N., Huberlant S., Bourhis-Lefebvre V. et al. Female obesity is negatively associated with live birth rate following IVF: a systematic review and meta-analysis. Hum Reprod Update. 2019;25(4):439–451. DOI: 10.1093/humupd/dmz011
5. Teede H.J., Khomami M.B., Morman R. et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026;407(10545):2329–2339. DOI: 10.1016/S0140-6736(26)00717-8
6. Wei S., Schmidt M.D., Dwyer T. et al. Obesity and menstrual irregularity: associations with SHBG, testosterone, and insulin. Obesity (Silver Spring). 2009;17(5):1070–1076. DOI: 10.1038/oby.2008.641
7. Itoi S., Sampei M., Tatsumi T. et al. Body mass index and menstrual irregularity in a prospective cohort study of smartphone application users. npj Women's Health. 2025;3(1):16. DOI: 10.1038/s44294-025-00065-z
8. Gesink Law D.C., Maclehose R.F., Longnecker M.P. Obesity and time to pregnancy. Hum Reprod. 2007;22(2):414–420. DOI: 10.1093/humrep/del400
9. Van der Steeg J.W., Steures P., Eijkemans M.J.C. et al. Obesity affects spontaneous pregnancy chances in subfertile, ovulatory women. Hum Reprod. 2008;23(2):324–328. DOI: 10.1093/humrep/dem371
10. Boxem A.J., Blaauwendraad S.M., Mulders A.G.M.G.J. et al. Preconception and Early-Pregnancy Body Mass Index in Women and Men, Time to Pregnancy, and Risk of Miscarriage. JAMA Netw Open. 2024;7(9):e2436157. DOI: 10.1001/jamanetworkopen.2024.36157
11. Diamanti-Kandarakis E., Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications for pathogenesis. Endocr Rev. 2012;33(6):981–1030. DOI: 10.1210/er.2011-1034
12. Patel A.H., Koysombat K., Pierret A. et al. Kisspeptin in functional hypothalamic amenorrhea: Pathophysiology and therapeutic potential. Ann N Y Acad Sci. 2024;1540(1):21–46. DOI: 10.1111/nyas.15220
13. Chen Y., Wang R., Zhang N., Xu L. The dual burden of obesity: decoding metabolism and female reproductive endocrinology. Front Physiol. 2025;16:1627607. DOI: 10.3389/fphys.2025.1627607
14. Broughton D.E., Moley K.H. Obesity and female infertility: potential mediators of obesity's impact. Fertil Steril. 2017;107(4):840–847. DOI: 10.1016/j.fertnstert.2017.01.017
15. Stothard B.J., Tennant P.W.G., Bell R. et al. Maternal overweight and obesity and the risk of congenital anomalies: a systematic review and meta-analysis. JAMA. 2009;301(6):636–650. DOI: 10.1001/jama.2009.113
16. Chu S.Y., Callaghan W.M., Kim S.Y. et al. Maternal obesity and risk of gestational diabetes mellitus. Diabetes Care. 2007;30(8):2070–2076. DOI: 10.2337/dc06-2559a
17. O'Brien T.E., Ray J.G., Chan W.S. Maternal body mass index and the risk of preeclampsia: a systematic overview. Epidemiology. 2003;14(3):368–374. DOI: 10.1097/00001648-200305000-00020
18. Chu S.Y., Kim S.Y., Schmid C.H. et al. Maternal obesity and risk of cesarean delivery: a meta-analysis. Obes Rev. 2007;8(5):385–394. DOI: 10.1111/j.1467-789X.2007.00397.x
19. Zhang C., Wu Y., Li S., Zhang D. Maternal prepregnancy obesity and the risk of shoulder dystocia: a meta-analysis. BJOG. 2018;125(4):407–413. DOI: 10.1111/1471-0528.14841
20. Zhang J., Bricker L., Wray S., Quenby S. Poor uterine contractility in obese women. BJOG. 2007;114(3):343–348. DOI: 10.1111/j.1471-0528.2006.01233.x
21. Heslehurst N., Simpson H., Ells L.J. et al. The impact of maternal BMI status on pregnancy outcomes with immediate short-term obstetric resource implications: a meta-analysis. Obes Rev. 2008;9(6):635–683. DOI: 10.1111/j.1467-789X.2008.00511.x
22. Rasmussen K.M., Kjolhede C.L. Prepregnant overweight and obesity diminish the prolactin response to suckling in the first week postpartum. Pediatrics. 2004;113(5):e465–e471. DOI: 10.1542/peds.113.5.e465
23. Sharp G.C., Salas L.A., Monnereau C. et al. Maternal BMI at the start of pregnancy and offspring epigenome-wide DNA methylation: findings from the pregnancy and childhood epigenetics (PACE) consortium. Hum Mol Genet. 2017;26(20):4067–4085. DOI: 10.1093/hmg/ddx290
24. Aune D., Saugstad O.D., Henriksen T., Tonstad S. Maternal body mass index and the risk of fetal death, stillbirth, and infant death: a systematic review and meta-analysis. JAMA. 2014;311(15):1536–1546. DOI: 10.1001/jama.2014.2269
25. American Diabetes Association. 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes — 2025. Diabetes Care. 2025;48(Suppl 1):S306–S320. DOI: 10.2337/dc25-S015
26. Sustarsic A., Hadzic V., Meulenberg C.J.W. et al. The influence of lifestyle interventions and overweight on infertility: a systematic review, meta-analysis, and meta-regression of randomized controlled trials. Front Med (Lausanne). 2023;10:1264947. DOI: 10.3389/fmed.2023
27. Legro R.S., Hansen K.R., Diamond M.P. et al. Effects of preconception lifestyle intervention in infertile women with obesity: the FIT-PLESE randomized controlled trial. PLoS Med. 2022;19(1):e1003883. DOI: 10.1371/journal.pmed.1003883
28. Wang Z., Van Faassen M., Groen H. et al. Resumption of ovulation in anovulatory women with PCOS and obesity is associated with reduction of 11β-hydroxyandrostenedione concentrations. Hum Reprod. 2024;39(5):1078–1088. DOI: 10.1093/humrep/deae058
29. Coskun T., Sloop K.W., Loghin C. et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3–14. DOI: 10.1016/j.molmet.2018.09.009
30. Look M., Dunn J.P., Kushner R.F. et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720–2729. DOI: 10.1111/dom.16275
31. Tchang B.G., Mihai A.C., Stefanski A. et al. Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program. Obesity (Silver Spring). 2025;33(5):851–860. DOI: 10.1002/oby.24254
32. Aronne L.J., Horn D.B., le Roux C.W. et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26–36. DOI: 10.1056/NEJMoa2416394
33. Pi-Sunyer X., Astrup A., Fujioka K. et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22. DOI: 10.1056/NEJMoa1411892
34. Wilding J.P.H., Batterham R.L., Calanna S. et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. DOI: 10.1056/NEJMoa2032183
35. Kolli R.T., Aoutla S., Jyothi N. et al. Rebound or Retention: A Meta-Analysis of Weight Regain After the Discontinuation of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Other Anti-obesity Drugs. Cureus. 2025;17(10):e94926. DOI: 10.7759/cureus.94926
36. Aronne L.J., Sattar N., Horn D.B. et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38–48. DOI: 10.1001/jama.2023.24945
37. Broughton D.E., Jungheim E.S. A focused look at obesity and the preimplantation trophoblast. Semin Reprod Med. 2016;34(1):5–10. DOI: 10.1055/s-0035-1570032
38. De-Regil L.M., Palacios C., Lombardo L.K. et al. Vitamin D supplementation for women during pregnancy. Cochrane Database Syst Rev. 2016;(1):CD008873. DOI: 10.1002/14651858.CD008873.pub3
39. Hviid K.V.R., Banasik K., Mortensen L.H. et al. Periconceptional GLP-1 receptor agonist exposure and obstetric outcomes: a Danish nationwide cohort study. Hum Reprod Open. 2026;2026(2):hoag015. DOI: 10.1093/hropen/hoag015
40. Dao K., Shechtman S., Weber-Schoendorfer C. et al. Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services. BMJ Open. 2024;14(4):e083550. DOI: 10.1136/bmjopen-2023-083550
41. Cesta C.E., Rotem R., Bateman B.T. et al. Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy. JAMA Intern Med. 2024;184(2):144–152. DOI: 10.1001/jamainternmed.2023.6663
42. Liu X., Xiong B., Yang R. et al. Periconceptional use of GLP-1 receptor agonists and the risk of major congenital malformations: a systematic review and meta-analysis. Endocr Connect. 2026;15(7):e260280. DOI: 10.1530/EC-26-0280
43. Brown J.P., Huybrechts K.F., Straub L. et al. Continuing Glucagon-Like Peptide-1 Receptor Agonists Into the First Trimester of Pregnancy and Pregnancy Outcomes: A Target Trial Emulation Study Using Claims Information. Ann Intern Med. 2026;179(7):929–937. DOI: 10.7326/ANNALS-25-04820
44. Uysal N., Horoz E., Gungor M. et al. Pregnancy outcomes following maternal GLP-1 receptor agonist exposure: a systematic review and meta-analysis. Sci Rep. 2026. DOI: 10.1038/s41598-026-61582-8
45. Kodali L.S.M., Metlock F.E., Nriagu B.N. et al. GLP-1 receptor agonist exposure during pregnancy: a systematic review and meta-analysis of adverse pregnancy outcomes. JACC Adv. 2026;5(6):102649. DOI: 10.1016/j.jacadv.2026.102649
46. Ozbek L., Shah E., Al-Shiab R. et al. Safety of GLP-1 and dual GLP-1/GIP receptor agonists in preconception, pregnancy, and lactation: a systematic review of maternal, fetal, and neonatal outcomes. Diabetes Obes Metab. 2026;28(6):4503–4528. DOI: 10.1111/dom.70699
47. Banerjee M., Dutta S., Dasgupta S. Pre-pregnancy GLP-1 receptor agonist or tirzepatide use and gestational diabetes risk: evaluating pharmacodynamic carry-over versus post-discontinuation metabolic rebound in a multinational federated cohort. Diabetes Obes Metab. 2026;28(7):6370–6379. DOI: 10.1111/dom.70853
48. Goldstein R.F., Bahri Khomami M., Tay C.T. et al. Gestational weight gain and risk of adverse maternal and neonatal outcomes in observational data from 1.6 million women: systematic review and meta-analysis. BMJ. 2025;391:e085710. DOI: 10.1136/bmj-2025-085710
49. Ye X., Li P., Shi C. Association between gestational weight gain and adverse pregnancy outcomes: a systematic review and meta-analysis. Front Glob Womens Health. 2026;7:1777069. DOI: 10.3389/fgwh.2026.1777069
50. Yang D., Yu Z., Chen J. et al. Association Between First-Trimester Gestational Weight Gain and the Risks of Gestational Diabetes Mellitus and Macrosomia. Diabetes Metab Syndr Obes. 2026;19:564746. DOI: 10.2147/DMSO.S564746
51. Луговик И.А., Бабина А.В., Арутюнян С.С. и др. Первый дженерик тирзепатида GP30931: физико-химическое и биологическое сходство с референтным лекарственным средством. Разработка и регистрация лекарственных средств. 2025;14(2):54–74. DOI: 10.33380/2305-2066-2025-14-2-2084. Lugovik I.A., Babina A.V., Arutyunyan S.S. et al. The first generic tirzepatide GP30931: physicochemical and biological similarity to the reference drug. Drug development & registration. 2025;14(2):54–74 (in Russ.) DOI: 10.33380/2305-2066-2025-14-2-2084
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать